drugset

drugset / Trial / NCT05383274

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

NCT05383274 ↗

Phase 4 Recruiting 34 enrolled Urotronic Inc. Laborie Medical Technologies Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.

Timeline

Start: 2022-02-14
Primary completion: 2026-06-30
Completion: 2026-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	—	—

Indications